ArticleJournal of cancer research and clinical oncology2023

Osimertinib is a dual inhibitor of hepatocellular carcinoma and angiogenesis in an EGFR-independent manner, and synergizes with venetoclax.

Qiaoxin Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.